Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab compared with placebo, according to a presenter at the American Academy of ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback